Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

...

Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results

Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results

...

Olon Continues its Growth Path and Announces a New Acquisition

Olon Continues its Growth Path and Announces a New Acquisition

...

Olon Group Announces the Acquisition of GTP Bioways Group

Olon Group Announces the Acquisition of GTP Bioways Group

...

Societal CDMO to Participate at 35th Annual Roth

Societal CDMO to Participate at 35th Annual Roth

SAN DIEGO and GAINESVILLE, Ga., March 03, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract......

menu
menu